First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

NCT00981058 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1093

Last updated 2025-06-18

Study results available
· View outcomes & findings →

Summary

The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

BIOLOGICAL

Necitumumab

Administered intravenously. Continues until progressive disease, toxicity, noncompliance, or withdrawal.

DRUG

Gemcitabine

Administered intravenously. Continues for a maximum of six cycles.

DRUG

Cisplatin

Administered intravenously. Continues for a maximum of six cycles.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY
  • PPD Development, LP

    collaborator INDUSTRY
  • Medidata Solutions

    collaborator INDUSTRY
  • Laboratory Corporation of America

    collaborator INDUSTRY
  • University of Colorado, Denver

    collaborator OTHER
  • Thermo Fisher Scientific FS

    collaborator OTHER
  • ICON Clinical Research

    collaborator INDUSTRY
  • Pacific Biomarkers

    collaborator OTHER
  • Sysmex Inostics GmbH

    collaborator INDUSTRY
  • Intertek

    collaborator INDUSTRY
  • Eli Lilly and Company

    lead INDUSTRY

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-07
Primary Completion
2013-06-17
Completion
2024-05-30

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Croatia
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Philippines
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Singapore
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981058 on ClinicalTrials.gov